Product Code: 27EL-778-2035
Please note: This is a Single Viewer eCast registration for one participant for this eCast for both the live and on-demand version of this eCast. If you are interested in presenting this program to a group, please see the “eCast Registration Form– Group Viewing” form on the eCast program page.
Access instructions for the live eCast will be provided via email approximately 2-3 business days prior to the live program date. Access instructions for the on-demand version of this program will be provided via email approximately 3-10 business days after the live program has occurred and the on-demand version is available.
Program Description: Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD19 has revolutionized the landscape of cancer care, offering unprecedented response rates and durable remissions for patients with refractory B-cell malignancies. Building on this oncological success, clinical observations of rapid B-cell depletion and subsequent immune system "resets" have sparked a major paradigm shift toward treating non-malignant conditions. Today, an increasing number of clinical trials are actively exploring CAR-T cell therapy as an intervention for treatment-resistant autoimmune diseases. This emerging frontier spans a diverse range of medical specialties—including rheumatology, dermatology, neurology, and transplant medicine—offering the potential to transition patients from temporary disease management to long-term, drug-free remission.
Instructional methods will include, but may not be limited to, background discussion, use case demonstrations, case studies, and question and answer at the conclusion of the eCast.